Marius Erik Mayerhoefer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1814526/publications.pdf

Version: 2024-02-01

133 papers 4,963 citations

39 h-index 62 g-index

145 all docs

145 docs citations

145 times ranked 6433 citing authors

#	Article	lF	CITATIONS
1	Introduction to Radiomics. Journal of Nuclear Medicine, 2020, 61, 488-495.	2.8	673
2	Effects of MRI acquisition parameter variations and protocol heterogeneity on the results of texture analysis and pattern discrimination: An applicationâ€oriented study. Medical Physics, 2009, 36, 1236-1243.	1.6	183
3	Performance of Whole-Body Integrated ¹⁸ F-FDG PET/MR in Comparison to PET/CT for Evaluation of Malignant Bone Lesions. Journal of Nuclear Medicine, 2014, 55, 191-197.	2.8	134
4	Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. Lancet Haematology,the, 2017, 4, e595-e606.	2.2	130
5	Multidisciplinary Recommendations Regarding Post-Vaccine Adenopathy and Radiologic Imaging: <i>Radiology</i> Scientific Expert Panel. Radiology, 2021, 300, E323-E327.	3.6	117
6	²³ Na MR Imaging at 7 T after Knee Matrix–associated Autologous Chondrocyte Transplantation Preliminary Results. Radiology, 2010, 257, 175-184.	3.6	103
7	Detection of degenerative cartilage disease: comparison of high-resolution morphological MR and quantitative T2 mapping at 3.0 Tesla. Osteoarthritis and Cartilage, 2010, 18, 1211-1217.	0.6	100
8	Texture-based classification of different gastric tumors at contrast-enhanced CT. European Journal of Radiology, 2013, 82, e537-e543.	1.2	100
9	Evaluation of Diffusion-Weighted MRI for Pretherapeutic Assessment and Staging of Lymphoma: Results of a Prospective Study in 140 Patients. Clinical Cancer Research, 2014, 20, 2984-2993.	3.2	100
10	PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 51-60.	3.3	98
11	Textureâ€based and diffusionâ€weighted discrimination of parotid gland lesions on MR images at 3.0 Tesla. NMR in Biomedicine, 2013, 26, 1372-1379.	1.6	94
12	Skeletal Muscle Depletion and Markers for Cancer Cachexia Are Strong Prognostic Factors in Epithelial Ovarian Cancer. PLoS ONE, 2015, 10, e0140403.	1.1	92
13	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 2016, 1, e000097.	2.0	82
14	Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood, 2019, 134, 1132-1143.	0.6	81
15	Textureâ€based classification of focal liver lesions on MRI at 3.0 Tesla: A feasibility study in cysts and hemangiomas. Journal of Magnetic Resonance Imaging, 2010, 32, 352-359.	1.9	80
16	Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT–Controlled Prospective Study in 64 Patients. Clinical Cancer Research, 2015, 21, 2506-2513.	3.2	78
17	Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. Cancer Discovery, 2022, 12, 372-387.	7.7	77
18	Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer. European Journal of Radiology, 2010, 73, 294-299.	1.2	66

#	Article	IF	Citations
19	Shoulder Impingement: Relationship of Clinical Symptoms and Imaging Criteria. Clinical Journal of Sport Medicine, 2009, 19, 83-89.	0.9	64
20	Evaluation of native hyaline cartilage and repair tissue after two cartilage repair surgery techniques with 23Na MR imaging at 7ÂT: initial experience. Osteoarthritis and Cartilage, 2012, 20, 837-845.	0.6	63
21	STIR vs. T1-weighted fat-suppressed gadolinium-enhanced MRI of bone marrow edema of the knee: Computer-assisted quantitative comparison and influence of injected contrast media volume and acquisition parameters. Journal of Magnetic Resonance Imaging, 2005, 22, 788-793.	1.9	61
22	Effects of Magnetic Resonance Image Interpolation on the Results of Texture-Based Pattern Classification. Investigative Radiology, 2009, 44, 405-411.	3.5	59
23	First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. Blood, 2017, 130, 2499-2503.	0.6	59
24	18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma. Investigative Radiology, 2016, 51, 163-169.	3.5	58
25	Non-Invasive Assessment of Breast Cancer Molecular Subtypes with Multiparametric Magnetic Resonance Imaging Radiomics. Journal of Clinical Medicine, 2020, 9, 1853.	1.0	57
26	High-resolution cartilage imaging of the knee at 3T: Basic evaluation of modern isotropic 3D MR-sequences. European Journal of Radiology, 2011, 78, 398-405.	1.2	56
27	Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors. Clinical Nuclear Medicine, 2017, 42, 669-674.	0.7	56
28	Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2760-2769.	3.3	55
29	Incorporating radiomics into clinical trials: expert consensus endorsed by the European Society of Radiology on considerations for data-driven compared to biologically driven quantitative biomarkers. European Radiology, 2021, 31, 6001-6012.	2.3	53
30	Texture analysis for tissue discrimination on T1-weighted MR images of the knee joint in a multicenter study: Transferability of texture features and comparison of feature selection methods and classifiers. Journal of Magnetic Resonance Imaging, 2005, 22, 674-680.	1.9	51
31	A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. Blood, 2017, 129, 383-385.	0.6	51
32	Are signal intensity and homogeneity useful parameters for distinguishing between benign and malignant soft tissue masses on MR images?. Magnetic Resonance Imaging, 2008, 26, 1316-1322.	1.0	50
33	Functional imaging in head and neck squamous cell carcinoma: correlation of PET/CT and diffusion-weighted imaging at 3ÂTesla. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1009-1019.	3.3	50
34	Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non–Small Cell Lung Cancer. Clinical Nuclear Medicine, 2019, 44, 535-543.	0.7	48
35	Comparison of MRI and Conventional Radiography for Assessment of Acromial Shape. American Journal of Roentgenology, 2005, 184, 671-675.	1.0	45
36	[68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia. Investigative Radiology, 2018, 53, 403-408.	3.5	45

#	Article	IF	Citations
37	The in vivo effects of unloading and compression on T1-Gd (dGEMRIC) relaxation times in healthy articular knee cartilage at 3.0 Tesla. European Radiology, 2010, 20, 443-449.	2.3	42
38	Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [⁶⁸ Ga]Ga-Pentixafor-PET/MRI. Theranostics, 2019, 9, 3653-3658.	4.6	42
39	Short-term outcome of painful bone marrow oedema of the knee following oral treatment with iloprost or tramadol: results of an exploratory phase II study of 41 patients. Rheumatology, 2007, 46, 1460-1465.	0.9	41
40	Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen. European Radiology, 2013, 23, 1978-1985.	2.3	41
41	Association Between Osteogenesis and Inflammation During the Progression of Calcified Plaque Evaluated by ¹⁸ F-Fluoride and ¹⁸ F-FDG. Journal of Nuclear Medicine, 2017, 58, 968-974.	2.8	40
42	Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). Annals of Hematology, 2014, 93, 249-253.	0.8	39
43	Quantitative assessment of atherosclerotic plaques on 18F-FDG PET/MRI: comparison with a PET/CT hybrid system. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1503-1512.	3.3	38
44	Retrospective comparison of the effectiveness of various treatment modalities of extragastric MALT lymphoma: a single-center analysis. Annals of Hematology, 2014, 93, 1287-1295.	0.8	37
45	[18F]DOPA PET/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2159-2169.	3.3	35
46	Clinical Features, Treatment and Outcome of Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma of the Ocular Adnexa: Single Center Experience of 60 Patients. PLoS ONE, 2014, 9, e104004.	1.1	35
47	¹¹ C-Methionine PET/CT Imaging of ^{99m} Tc-MIBI-SPECT/CT-Negative Patients With Primary Hyperparathyroidism and Previous Neck Surgery. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4199-4205.	1.8	32
48	Sodium MR Imaging of Achilles Tendinopathy at 7 T: Preliminary Results. Radiology, 2012, 262, 199-205.	3.6	31
49	Quantitative analysis of lumbar intervertebral disc abnormalities at 3.0 Tesla: value of <i>T</i> ₂ texture features and geometric parameters. NMR in Biomedicine, 2012, 25, 866-872.	1.6	31
50	Texture-Based Analysis of 100 MR Examinations of Head and Neck Tumors – Is It Possible to Discriminate Between Benign and Malignant Masses in a Multicenter Trial?. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2016, 188, 195-202.	0.7	31
51	Diffusion weighted imaging: Lymph nodes. European Journal of Radiology, 2010, 76, 398-406.	1.2	29
52	Assessment of pulmonary melanoma metastases with 18F-FDG PET/CT: which PET-negative patients require additional tests for definitive staging?. European Radiology, 2012, 22, 2451-2457.	2.3	28
53	Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [¹¹ C]acetate PET as a prognostic marker. Prostate, 2015, 75, 1760-1767.	1.2	28
54	MRI and PET/MRI in hematologic malignancies. Journal of Magnetic Resonance Imaging, 2020, 51, 1325-1335.	1.9	28

#	Article	IF	Citations
55	Performance of integrated FDG-PET/contrast-enhanced CT in the staging and restaging of colorectal cancer: Comparison with PET and enhanced CT. European Journal of Radiology, 2010, 73, 324-328.	1.2	27
56	Sustained Response to Vemurafenib in a <i>BRAF^{V600E}</i> Hutated Anaplastic Thyroid Carcinoma Patient. Thyroid, 2016, 26, 1515-1516.	2.4	27
57	PET/MRI for Oncologic Brain Imaging: A Comparison of Standard MR-Based Attenuation Corrections with a Model-Based Approach for the Siemens mMR PET/MR System. Journal of Nuclear Medicine, 2017, 58, 1519-1525.	2.8	27
58	Single-Cell RNA Sequencing Reveals Tissue Compartment-Specific Plasticity of Mycosis Fungoides Tumor Cells. Frontiers in Immunology, 2021, 12, 666935.	2.2	27
59	CXCR4 PET imaging of mantle cell lymphoma using [⁶⁸ Ga]Pentixafor: comparison with [¹⁸ F]FDG-PET. Theranostics, 2021, 11, 567-578.	4.6	26
60	Computer-Assisted Quantitative Analysis of Bone Marrow Edema of the Knee: Initial Experience with a New Method. American Journal of Roentgenology, 2004, 182, 1399-1403.	1.0	24
61	[18F]FDG-PET/CT Radiomics for Prediction of Bone Marrow Involvement in Mantle Cell Lymphoma: A Retrospective Study in 97 Patients. Cancers, 2020, 12, 1138.	1.7	24
62	Ultra-early response assessment in lymphoma treatment: [18F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72Âhours of treatment. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 931-940.	3.3	23
63	CXCR4 PET/MRI for follow-up of gastric mucosa–associated lymphoid tissue lymphoma after first-line <i>HelicobacterÂpylori</i> eradication. Blood, 2022, 139, 240-244.	0.6	22
64	Feasibility of Texture Analysis for the Assessment of Biochemical Changes in Meniscal Tissue on T1 Maps Calculated From Delayed Gadolinium-Enhanced Magnetic Resonance Imaging of Cartilage Data. Investigative Radiology, 2010, 45, 543-547.	3.5	20
65	Threeâ€dimensional texture analysis of contrast enhanced CT images for treatment response assessment in Hodgkin lymphoma: Comparison with Fâ€18â€FDG PET. Medical Physics, 2014, 41, 121904.	1.6	20
66	Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?. Clinical Nuclear Medicine, 2016, 41, 101-105.	0.7	20
67	Treatment of mucosa associated lymphoid tissue lymphoma with a longâ€term onceâ€weekly regimen of oral azithromycin: Results from the phase II MALT—A trial. Hematological Oncology, 2019, 37, 22-26.	0.8	20
68	Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen?. European Radiology, 2012, 22, 938-946.	2.3	19
69	Assessment of Central Nervous System Lymphoma Based on CXCR4 Expression In Vivo Using 68Ga-Pentixafor PET/MRI. Clinical Nuclear Medicine, 2021, 46, 16-20.	0.7	19
70	Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?. Clinical Nuclear Medicine, 2016, 41, 837-843.	0.7	18
71	ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016. Annals of Oncology, 2016, 27, 1378-1381.	0.6	18
72	Reproducibility of MRI Dixon-Based Attenuation Correction in Combined PET/MR with Applications for Lean Body Mass Estimation. Journal of Nuclear Medicine, 2016, 57, 1096-1101.	2.8	18

#	Article	IF	CITATIONS
7 3	Visceral Pleural Invasion in Pulmonary Adenocarcinoma: Differences in CT Patterns between Solid and Subsolid Cancers. Radiology: Cardiothoracic Imaging, 2019, 1, e190071.	0.9	17
74	Functional imaging using radiomic features in assessment of lymphoma. Methods, 2021, 188, 105-111.	1.9	17
75	High-resolution Magnetic Resonance Imaging and Conventional Magnetic Resonance Imaging on a Standard Field-strength Magnetic Resonance System Compared to Arthroscopy in Patients with Suspected Meniscal Tears. Academic Radiology, 2008, 15, 928-933.	1.3	16
76	MRI-Demonstrated Outcome of Subchondral Stress Fractures of the Knee After Treatment with Iloprost or Tramadol: Observations in 14 Patients. Clinical Journal of Sport Medicine, 2008, 18, 358-362.	0.9	16
77	Correlation between glycolytic activity on [18F]â€FDGâ€PET and cell density on diffusionâ€weighted MRI in lymphoma at staging. Journal of Magnetic Resonance Imaging, 2018, 47, 1217-1226.	1.9	16
78	Transformed mucosaâ€associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reactionâ€based clonality analysis. British Journal of Haematology, 2019, 186, 448-459.	1.2	16
79	Texture Bags: Anomaly Retrieval in Medical Images Based on Local 3D-Texture Similarity. Lecture Notes in Computer Science, 2012, , 116-127.	1.0	16
80	Does weight force application to the lower torso have an influence on inferior vena cava and cardiovascular parameters?. American Journal of Emergency Medicine, 2008, 26, 603-607.	0.7	15
81	Delayed Efficacy After Treatment With Lenalidomide or Thalidomide in Patients With Mucosa-Associated Lymphoid Tissue Lymphoma. Oncologist, 2016, 21, 72-75.	1.9	15
82	PET/MRI for neuroendocrine tumors: a match made in heaven or just another hype?. Clinical and Translational Imaging, 2019, 7, 405-413.	1.1	15
83	RECIL Versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients. Cancers, 2020, 12, 9.	1.7	15
84	Influence of PET reconstruction technique and matrix size on qualitative and quantitative assessment of lung lesions on [18F]-FDG-PET: A prospective study in 37 cancer patients. European Journal of Radiology, 2017, 90, 20-26.	1.2	14
85	Combination of Radiomics and Machine Learning with Diffusion-Weighted MR Imaging for Clinical Outcome Prognostication in Cervical Cancer. Tomography, 2021, 7, 344-357.	0.8	14
86	Bone Marrow Involvement in Malignant Lymphoma. Academic Radiology, 2018, 25, 453-460.	1.3	13
87	Radiomics of high-resolution computed tomography for the differentiation between cholesteatoma and middle ear inflammation: effects of post-reconstruction methods in a dual-center study. European Radiology, 2021, 31, 4071-4078.	2.3	13
88	18F FDG PET/MRI with hepatocyte-specific contrast agent for M staging of rectal cancer: a primary economic evaluation. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3268-3276.	3.3	13
89	Abnormal findings in hallucal sesamoids on MR imaging—Associated with different pathologies of the forefoot? An observational study. European Journal of Radiology, 2010, 74, 226-230.	1.2	12
90	Rapid Detection of Bone Metastasis at Thoracoabdominal CT: Accuracy and Efficiency of a New Visualization Algorithm. Radiology, 2014, 270, 825-833.	3.6	12

#	Article	IF	CITATIONS
91	Transformed mycosis fungoides: bridging to allogeneic stem cell transplantation with brentuximab vedotin. Leukemia and Lymphoma, 2016, 57, 206-208.	0.6	12
92	A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone Bâ€cell lymphoma of the mucosaâ€associated lymphoid tissue (<scp>MALT)</scp> lymphoma. Hematological Oncology, 2018, 36, 49-55.	0.8	12
93	Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone Bâ€cell lymphoma of the mucosaâ€associated lymphoid tissue (MALT lymphoma). Hematological Oncology, 2018, 36, 62-67.	0.8	12
94	Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use. Pathology, 2021, 53, 385-399.	0.3	12
95	Relevance of calcitonin cut-off in the follow-up of medullary thyroid carcinoma for conventional imaging and 18-fluorine-fluorodihydroxyphenylalanine PET. Anticancer Research, 2014, 34, 6647-54.	0.5	12
96	Oblique MR imaging of the anterior cruciate ligament based on threeâ€dimensional orientation. Journal of Magnetic Resonance Imaging, 2007, 26, 794-798.	1.9	11
97	Assessement of rheumatic diseases with computational radiology: Current status and future potential. European Journal of Radiology, 2009, 71, 211-216.	1.2	11
98	Prolonged followâ€up on lenalidomideâ€based treatment for mucosaâ€associated lymphoid tissue lymphoma (MALT lymphoma)—Realâ€world data from the Medical University of Vienna. Hematological Oncology, 2019, 37, 345-351.	0.8	11
99	Pre-Therapeutic Total Lesion Glycolysis on [18F]FDG-PET Enables Prognostication of 2-Year Progression-Free Survival in MALT Lymphoma Patients Treated with CD20-Antibody-Based Immunotherapy. Molecular Imaging and Biology, 2019, 21, 1192-1199.	1.3	11
100	Evaluation of [18F]-FDG-Based Hybrid Imaging Combinations for Assessment of Bone Marrow Involvement in Lymphoma at Initial Staging. PLoS ONE, 2016, 11, e0164118.	1.1	10
101	Whole-Body [18F]FDG-PET/MRI vs. [18F]FDG-PET/CT in Malignant Melanoma. Molecular Imaging and Biology, 2020, 22, 739-744.	1.3	10
102	Positive selection as the unifying force for clonal evolution in multiple myeloma. Leukemia, 2021, 35, 1511-1515.	3. 3	10
103	The role of 18F-FDG PET/CT radiomics in lymphoma. Clinical and Translational Imaging, 2021, 9, 589-598.	1.1	10
104	Gadolinium diethylenetriaminepentaacetate enhancement kinetics in the menisci of asymptomatic subjects: a first step towards a dedicated dGEMRIC (delayed gadoliniumâ€enhanced MRI of cartilage)â€ike protocol for biochemical imaging of the menisci. NMR in Biomedicine, 2011, 24, 1210-1215.	1.6	9
105	Clarithromycin Leading to Complete Remission in the First-Line Treatment of Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma. Journal of Clinical Oncology, 2015, 33, e130-e132.	0.8	8
106	Particular findings on lung CT in patients undergoing immunotherapy for bronchogenic carcinoma. Wiener Klinische Wochenschrift, 2020, 132, 467-474.	1.0	8
107	Gender Aspects in Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue: Does Sex Matter?. Oncology, 2016, 91, 243-250.	0.9	7
108	A pilot study of confocal laser endomicroscopy for diagnosing gastrointestinal mucosa-associated lymphoid tissue (MALT) lymphoma. Surgical Endoscopy and Other Interventional Techniques, 2016, 30, 2879-2885.	1.3	7

#	Article	IF	Citations
109	Depth of Remission Following First-Line Treatment Is an Independent Prognostic Marker for Progression-Free Survival in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. Cancers, 2020, 12, 492.	1.7	7
110	In Human Visualization of Ibrutinib-Induced CLL Compartment Shift. Cancer Immunology Research, 2020, 8, 984-989.	1.6	7
111	Longâ€term safety and activity of cladribine in patients with extranodal Bâ€cell marginal zone lymphoma of the mucosaâ€associated lymphoid tissue (MALT) lymphoma. Hematological Oncology, 2017, 35, 177-186.	0.8	6
112	An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1522-1537.	3.3	6
113	(18)F-DOPA PET/CT and MRI: description of 12 histologically-verified pheochromocytomas. Anticancer Research, 2014, 34, 791-5.	0.5	6
114	Standardized Reporting of Oncologic Response: Making Every Report Count. Radiology Imaging Cancer, 2022, 4, .	0.7	5
115	Does elevated glucose metabolism correlate with higher cell density in Neurofibromatosis type 1 associated peripheral nerve sheath tumors?. PLoS ONE, 2017, 12, e0189093.	1.1	4
116	Successful Clarithromycin Monotherapy in a Patient with Primary Follicular Lymphoma of the Duodenum. Case Reports in Oncology, 2018, 11, 239-245.	0.3	4
117	Is there a reliable size cut-off for splenic involvement in lymphoma? A [18F]FDG-PET controlled study. PLoS ONE, 2019, 14, e0213551.	1.1	4
118	First Line Systemic Treatment for MALT Lymphomaâ€"Do We Still Need Chemotherapy? Real World Data from the Medical University Vienna. Cancers, 2020, 12, 3533.	1.7	4
119	Diffusion-Weighted MRI for Lymphoma Staging—Response. Clinical Cancer Research, 2015, 21, 222-223.	3.2	3
120	Diffusion-Weighted MRI for Lymphoma Restagingâ€"Response. Clinical Cancer Research, 2015, 21, 3809-3809.	3.2	3
121	DWI-MRI <i>vs</i> CT in gastric MALT lymphomaâ€"preliminary results in 19 patients. British Journal of Radiology, 2018, , 20180263.	1.0	3
122	Accuracy of PET quantification in [68Ga]Ga-pentixafor PET/MR imaging of carotid plaques. Journal of Nuclear Cardiology, 2022, 29, 492-502.	1.4	3
123	Imaging Inflammation in Atherosclerosis with CXCR4-Directed [68Ga]PentixaFor PET/MRIâ€"Compared with [18F]FDG PET/MRI. Life, 2022, 12, 1039.	1.1	3
124	Positron emission tomography/magnetic resonance imaging (PET/MRI) vs. gastroscopy: Can it improve detection of extranodal marginal zone lymphomas of the stomach following <i>H. pylori</i> treatment?. Expert Review of Hematology, 0, , 1-7.	1.0	2
125	Lymphoma in Danon disease with chronic rhabdomyolysis treated with EPOCH-R. Medicine (United) Tj ETQq1 1 (0.784314 0.4	rgBT /Overloc
126	Heavy black tea consumption and elevated CA 19-9 and CA 125 levels. A case report on a patient with ovarian endometriotic cysts. Gynecological Endocrinology, 2019, 35, 478-480.	0.7	1

#	Article	IF	CITATIONS
127	Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia. Blood, 2019, 134, 3965-3965.	0.6	1
128	Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial. Blood, 2020, 136, 2-4.	0.6	1
129	Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR. Blood, 2019, 134, 4037-4037.	0.6	1
130	Metabolic Tumor Volume and Total Lesion Glycolysis Can Predict Response to Very Low Dose Radiotherapy (4 Gy) in Indolent B-Cell Lymphomas. Blood, 2021, 138, 3518-3518.	0.6	1
131	Retrospective Comparison of the Effectiveness of Various Treatment Modalities of Extragastric MALT Lymphoma: A single center analysis. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S219.	0.2	0
132	Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies. Blood, 2017, 130, 855-855.	0.6	0
133	In Human Visualization of Ibrutinib-Induced CLL Compartment Shift. Blood, 2019, 134, 1750-1750.	0.6	0